This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NewAmsterdam Pharma’s 8K filing here.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- What is the S&P/TSX Index?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Technology Stocks Explained: Here’s What to Know About Tech
- 5 Dividend ETFs to Buy and Hold Forever
